WellPoint price target raised to $130 from $120 at Leerink Leerink believes WellPoint (WLP) has "strong negotiating leverage" against Express Scripts (ESRX) over the 10-year contract between the two companies. Leerink thinks the contract could be renewed early under more favorable rates for WellPoint. The firm raised its price target for shares to $130 and keeps an Outperform rating on the stock. Leerink also raised its price target for Express Scripts shares to $85 from $80.
Anthem added to Focus List at Citi Citi analyst Ralph Giacobbe added Anthem (ANTM) to his firm's Focus List. As Anthem and Express Scripts (ESRX) continue to negotiate their pharmacy benefits manager contract, the analyst sees UnitedHealth (UNH) as a potential alternative for Anthem. Regardless of the outcome, Anthem is in the "driver's seat for significant savings/upside," which is not reflected in the stock. Giacobbe tells investors in a research note. He keeps a Buy rating on the name with a $172 price target.